Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD

This article was originally published in The Gray Sheet

Executive Summary

Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.

Advertisement

Related Content

Eli Lilly Lawsuit Challenges CMS Coverage Standard For Alzheimer's Diagnostic
Imaging Groups Oppose CMS Coverage Proposal For Beta-Amyloid PET
Lilly Says CMS Review Of Beta-Amyloid PET Goes Beyond Medicare Statutory Criteria
The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research
Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans
Medicare Panel Finds Little Support For Amyloid PET Imaging Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032479

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel